Categories |
|
Cancer |
|
Biotechnology
Cancer
Consumer
Customer Relationship Management
Drug Delivery
eHealthcare Pharma
eHealthcare Physician
Generics
Healthcare
Medical Devices
OTC Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic Areas:
- Cardiovascular
- Central Nervous System
- Immune Disorders and Inflammation
- Infectious Diseases
- Oncology
- Women'sHealth
|
|
|
1- Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market 6-Jan--2005
Analysis of evolving dynamics in the cancer market, focusing on the top 20 cancer drugs by 2004 sales in the seven major pharmaceutical markets. Includes sales forecasts to 2014 in consideration of key events predicted to influence product revenues.
------------------------------------------------------------------------------------------------------------------------- |
2- Stakeholder Insight: Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged 22-Dec-2004
Key issues in the pancreatic adenocarcinoma market including current diagnosis and treatment patterns, clinical trial involvement, survival and key prescribing influences in the seven major pharmaceutical markets.
------------------------------------------------------------------------------------------------------------------------- |
3- Bladder Cancer - High Recurrence Rates, Targeted Therapy to Stem the Flow? 22-Oct-2004
Key issues in bladder cancer pharmacotherapy, including current treatment controversies, unmet needs, the possible role of targeted therapies in bladder cancer and profile of key agents in the development pipeline.
------------------------------------------------------------------------------------------------------------------------- |
4- Pipeline Insight: Cancer Overview - Numerous Diverse Drugs Approaching Fruition 19-Oct-2004
Analysis of Phase III agents for the treatment of ten tumor types (breast, prostate, non-small cell lung, colorectal, lymphoma, melanoma, ovarian, brain, pancreatic, head and neck), including sales forecasts to 2012 and Datamonitor drug assessment.
-------------------------------------------------------------------------------------------------------------------------
|
5- Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology 1-Aug-2004
A management report that assesses the role of targeted cancer therapies as a driver of growth in the cancer market and their future role potential
-------------------------------------------------------------------------------------------------------------------------
|
6- Pipeline Insight: Breast Cancer - Complex Combinations of Old and New? 16-Jul-2004
Analysis of drugs in development for the treatment of breast cancer, including global sales forecasts to 2012 and in-depth assessment of key late-stage developmental agents. Complex Combinations of Old and New?
------------------------------------------------------------------------------------------------------------------------- |
7- Pipeline Insight: Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline Targeted Therapies 14-Jul-2004
Profiles of key pipeline drugs for colorectal cancer, including sales forecasts to 2012, and their clinical/research and commercial attractiveness
------------------------------------------------------------------------------------------------------------------------- |
8- Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution?
20-Apr-2004
The role of EGFR inhibitors and the future trends for use of innovative agents in the non-small cell lung and colorectal cancer market.
------------------------------------------------------------------------------------------------------------------------- |
9- Stakeholder Insight: Lung Cancer - Third-Generation Cytotoxics Set to Dominate the Market 12-Feb-2004
Key issues in the lung cancer market including the current diagnosis and treatment patterns of small cell lung (SCLC) and non-small cell lung cancer (NSCLC) in the seven major markets.
------------------------------------------------------------------------------------------------------------------------- |
10- Pipeline Insight: Cancer Overview - Increasing Collaboration to Accommodate Increasing Fragmentation
17-Nov-2003
An insight into the phase III pipeline drugs currently indicated for the ten major tumor types.
------------------------------------------------------------------------------------------------------------------------- |
11- Prostate Cancer Insight - Profiting From Changing Treatment Patterns
12-Nov-2003
------------------------------------------------------------------------------------------------------------------------- |
12- Gastric Cancer Overview: On the brink of a market shake-up? 4-Nov-2003
Overview of current treatment modalities and analysis of drugs in development for gastric cancer.
------------------------------------------------------------------------------------------------------------------------- |
13- The Cancer Market Outlook to 2008 1-Oct-2003
The Cancer Market Outlook to 2008, provides a single source of key epidemiological, market and R&D data, together with detailed analysis of current market dynamics and future forecasts to 2008..
------------------------------------------------------------------------------------------------------------------------- |
14- Thrombosis in Cancer - Expanding Focus for Anticoagulants 15-Sep-2003
The report provides an overview of the role for anticoagulants in cancer patients, examining the potential of existing and R&D drugs, and key factors limiting their use.
------------------------------------------------------------------------------------------------------------------------- |
15- Oral Mucositis - Challenging the priorities of cancer therapy 22-Aug-2003
This brief provides an overview of the biological causes, epidemiology and risk factors associated with oral mucositis and an analysis of the current treatment methods used for oral mucositis.
------------------------------------------------------------------------------------------------------------------------- |
16- Pipeline Insight: Lung Cancer - Iressa Rises >From the Ashes? 24-Jul-2003
The report provides an analysis of key late-stage drugs in development for the treatment of lung cancer.
------------------------------------------------------------------------------------------------------------------------- |
17- Treatment of Elderly Cancer Patients - An Untapped Market Opportunity
8-Jul-2003
The report defines the size of the elderly cancer market, identify the key areas of development in NSCLC and breast cancer treatment for elderly patients and understand the importance of targeting your therapies to the elderly cancer population.
------------------------------------------------------------------------------------------------------------------------- |
18- Pipeline Insight: Angiogenesis inibitors. Diversification and expansion of the innovatives class driving the evolution of cancer treatment 27-Jun-2003
This report looks at the impact of innovative angiogenesis inhibtors on the cancer therapeutics sector.
------------------------------------------------------------------------------------------------------------------------- |
| |
| |
| |
| |
